Description
Recombinant monoclonal antibody to CD44v6. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma BIWA4. This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG1 format, for improved compatibility with existing reagents, assays and techniques.
Target
CD44v6
Target Alias Names
bivatuzumab, CD44 antigen, CDw44, Epican, Extracellular matrix receptor III, ECMR-III, GP90 lymphocyte homing/adhesion receptor, HUTCH-I, Heparan sulfate proteoglycan, Hermes antigen, Hyaluronate receptor, Phagocytic glycoprotein 1, PGP-1, Phagocytic glycoprotein I, PGP-I
Isotype/Mimetic
IgG1
Animal-Derived Biomaterials Used
No
Sequence Available
No
Original Discovery Method
recombinantly reformatted hybridoma (from pre-2020 immunisation)
Original Discovery Information Provided On Datasheet
Yes
Antibody/Binder Origins
Animal-dependent discovery (in vitro display, OR immunisation pre-2020), In vitro recombinant expression